The Fort Worth Press - Fentanyl trade unravels

USD -
AED 3.672498
AFN 64.999762
ALL 82.324126
AMD 360.539884
ANG 1.790403
AOA 917.999837
ARS 1545.654536
AUD 1.475394
AWG 1.8
AZN 1.702091
BAM 1.769883
BBD 2.014669
BDT 124.715381
BGN 1.77347
BHD 0.378283
BIF 3011.021908
BMD 1
BND 1.291151
BOB 11.678099
BRL 5.666303
BSD 1.000231
BTN 94.44641
BWP 14.015512
BYN 3.004037
BYR 19600
BZD 2.016692
CAD 1.42684
CDF 2314.999833
CHF 0.839045
CLF 0.025469
CLP 1002.376741
CNY 6.67175
CNH 6.67242
COP 3319.97
CRC 449.312832
CUC 1
CUP 24.064952
CVE 100.150155
CZK 22.133023
DJF 178.554905
DKK 6.779349
DOP 60.996961
DZD 137.215041
EGP 53.485567
ERN 15
ETB 164.576405
EUR 0.90689
FJD 2.27435
FKP 0.756889
GBP 0.756535
GEL 2.590271
GGP 0.756889
GHS 11.725036
GIP 0.756889
GMD 73.999527
GNF 8883.748356
GTQ 7.646644
GYD 209.264655
HKD 7.845275
HNL 26.963306
HRK 6.831965
HTG 131.491813
HUF 330.604024
IDR 18235.4
ILS 3.216698
IMP 0.756889
INR 94.2455
IQD 1520.116116
IRR 1913737.503992
ISK 123.929969
JEP 0.756889
JMD 158.434254
JOD 0.708975
JPY 159.736964
KES 130.049711
KGS 87.4355
KHR 4079.999705
KMF 447.000026
KPW 900.00035
KRW 1335.485024
KWD 0.31147
KYD 0.835579
KZT 446.945163
LAK 22570.87132
LBP 89792.715562
LKR 333.505692
LRD 170.463102
LSL 16.951422
LTL 2.95274
LVL 0.60489
LYD 6.463464
MAD 9.936862
MDL 18.213816
MGA 4555.721867
MKD 55.830725
MMK 2100.274506
MNT 3605.662913
MOP 8.103688
MRU 40.552456
MUR 47.620147
MVR 15.385792
MWK 1738.739965
MXN 18.52569
MYR 4.086097
MZN 63.898478
NAD 16.951422
NGN 1343.570268
NIO 36.90298
NOK 9.562975
NPR 151.114437
NZD 1.80926
OMR 0.385095
PAB 1.000231
PEN 3.411802
PGK 4.575679
PHP 63.960057
PKR 277.274459
PLN 3.994725
PYG 6207.891986
QAR 3.64425
RON 4.851899
RSD 106.55897
RUB 82.809516
RWF 1483.467138
SAR 3.82571
SBD 8.097697
SCR 13.874904
SDG 601.541949
SEK 10.070015
SGD 1.287865
SHP 0.752984
SLE 23.049834
SLL 20969.503664
SOS 573.048487
SRD 37.489734
STD 20697.981008
STN 22.225246
SVC 8.773983
SYP 13002.000337
SZL 16.946523
THB 33.874991
TJS 9.249966
TMT 3.5
TND 3.008501
TOP 2.40776
TRY 50.374755
TTD 6.806368
TWD 32.891399
TZS 2655.145825
UAH 45.588969
UGX 4131.053487
UYU 40.541335
UZS 12057.876355
VES 912.87925
VND 25725.5
VUV 120.320092
WST 2.810586
XAF 594.881002
XAG 0.02044
XAU 0.0002568624
XCD 2.70255
XCG 1.807139
XDR 0.707052
XOF 594.881002
XPF 108.325017
YER 236.549828
ZAR 16.93433
ZMK 9001.197903
ZMW 20.500748
ZWL 321.999592
SSP 5945.381189
MXV 2.080458
  • RIO

    -0.3300

    97.04

    -0.34%

  • CMSC

    -0.0400

    20.67

    -0.19%

  • RELX

    0.0000

    33.41

    0%

  • RBGPF

    0.0000

    67.95

    0%

  • BCE

    -0.0700

    21.99

    -0.32%

  • BCC

    -0.0300

    75.66

    -0.04%

  • GSK

    0.8600

    51.08

    +1.68%

  • JRI

    -0.0300

    11.52

    -0.26%

  • NGG

    -0.1200

    76.68

    -0.16%

  • CMSD

    0.0900

    20.54

    +0.44%

  • BTI

    -0.0800

    55.75

    -0.14%

  • AZN

    2.0200

    168.1

    +1.2%

  • BP

    -1.4200

    43.16

    -3.29%

  • RYCEF

    0.4600

    19.7

    +2.34%

  • VOD

    0.0700

    17.02

    +0.41%


Fentanyl trade unravels




Fentanyl, a synthetic opioid up to 50 times more powerful than heroin, has been at the centre of a catastrophic overdose crisis. After years of relentless expansion, the market that once claimed tens of thousands of lives annually is contracting. Preliminary data from the United States Centers for Disease Control and Prevention (CDC) indicate that estimated drug overdose deaths fell to about 80,000 in 2024, a 27 per cent decline from the record of more than 110,000 in 2023, signalling the largest one‑year drop in modern history. This article examines why the fentanyl business is faltering, exploring the interlocking impacts of supply‑chain disruption, international diplomacy, law‑enforcement operations and public‑health initiatives.

From Peak to Downturn
During the early 2020s, illicitly manufactured fentanyl flooded the North American drug market, becoming the leading cause of overdose deaths. The pandemic exacerbated the situation: social isolation and disrupted addiction treatment services contributed to a spike of nearly 110,000 U.S. overdose deaths in 2023. Most of those deaths involved fentanyl, which dealers used to replace or adulterate heroin, counterfeit prescription pills and cocaine. Yet by 2024 the tide had turned. CDC data show that overdose deaths fell by roughly 30,000 in one year, and preliminary numbers for 2025 suggest the decline is continuing. The decrease extends across most U.S. states, with notable reductions in Ohio and West Virginia. Such a sustained downward trend had not been seen in decades and prompted researchers to look beyond domestic policy interventions for an explanation.

Supply‑Chain Disruption and China’s Crackdown
One of the most significant drivers of the decline appears to be a disruption in the global supply of fentanyl and its precursors. Researchers analysing death trends in the United States and Canada found evidence of a sudden shortage of fentanyl on illicit markets beginning in mid‑2023. A Science journal study led by scholars at Stanford and the University of Maryland concluded that Chinese enforcement actions against chemical suppliers have curtailed exports of fentanyl precursors. Officials in Beijing shut down hundreds of companies, removed tens of thousands of online advertisements and arrested about 300 people after agreements with Washington to restrict the trade. The research suggests these moves reduced the availability of 4‑fluoroisobutyryl fentanyl and other precursors, causing the purity of seized fentanyl to fall and the price to rise. According to the DEA’s 2025 National Drug Threat Assessment, some Chinese suppliers have become wary of shipping controlled chemicals, aware that their government is enforcing updated counter‑narcotics treaties. Mexican fentanyl cooks report difficulty obtaining key precursors and are increasingly relying on designer chemicals to circumvent regulations.

Cartel Disruption and Enforcement
While precursor shortages have choked production, targeted law‑enforcement operations have also shaken the industry. White papers from the National Security Data and Policy Institute detail how the capture of Ovidio Guzmán López — a senior Sinaloa Cartel figure and son of Joaquín "El Chapo" Guzmán — in 2023 destabilised the cartel’s synthetic‑drug division. Experts point to a correlation between cartel ‘decapitation’ operations and sharp but temporary declines in fentanyl seizures and overdose deaths. The killing of Nemesio Oseguera Cervantes, leader of the Jalisco New Generation Cartel in late 2025, likewise rattled the market, although researchers caution that rival factions can quickly reconstitute production. The National Drug Threat Assessment notes that the Sinaloa and Jalisco cartels continue to dominate fentanyl production, but they face greater risk as Mexican and U.S. authorities cooperate to target laboratories and intercept shipments at the southwest border. Seizures at border crossings dropped from 29,000 kilograms in 2023 to 23,000 kilograms in 2024, reinforcing evidence of a supply contraction.

Public‑Health Measures and Changing Behaviour
The contraction of the fentanyl trade has amplified the effect of public‑health interventions. Increased distribution of the overdose‑reversal drug naloxone, expansion of medication‑assisted treatment programmes and billions of dollars in opioid settlement funds have collectively improved survival rates. Harm‑reduction services such as supervised consumption sites and drug‑checking kits have proliferated in major cities, allowing users to detect dangerous adulterants like xylazine and medetomidine. Younger Americans appear less likely to initiate opioid use than previous cohorts, and some long‑term users have died or shifted consumption patterns. These behavioural changes mean that a shrinking pool of susceptible individuals is exposed to an increasingly fragmented drug supply.

An Evolving Drug Market
Despite the current downturn, the illicit drug market is far from static. The DEA warns that declining fentanyl purity does not equate to reduced danger. To compensate for shortages, traffickers are mixing fentanyl with veterinary tranquilizers and new synthetic opioids such as nitazenes, which can be even more potent. The National Security Data and Policy Institute notes that precursor chemicals still arrive in Mexico’s Pacific ports such as Manzanillo, and cartels are diversifying sourcing through India and alternative trans‑shipment points. According to the DEA, the presence of xylazine in seized powder has risen steadily since 2020, increasing the risk of fatal respiratory depression and flesh‑rotting wounds. Nitazene analogues and other novel substances are appearing in toxicology reports at an accelerating rate in 2026, underscoring how quickly manufacturers pivot when confronted with enforcement pressure.

The sharp decline in fentanyl‑related deaths offers a glimmer of hope after years of escalating tragedy, but it is not a definitive victory. The current contraction appears to be driven primarily by disruptions in precursor supply, strategic cartel‑targeting operations and strengthened public‑health responses. Yet the same agility that allowed traffickers to flood markets with fentanyl enables them to adapt to enforcement, shifting to new chemicals, routes and business models. Sustained reductions in opioid mortality will require international cooperation to control chemical exports, continued pressure on manufacturing networks, wider access to treatment and harm‑reduction services, and public education to deter drug initiation. As policy makers debate how to allocate resources, the lesson of the fentanyl collapse is clear: comprehensive, co‑ordinated action across borders and disciplines can save lives.